Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Does infliximab prevent colectomy in acute and chronic active ulcerative colitis?

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Outcomes Following Pouch Formation in Paediatric Ulcerative Colitis: A Study from the Porto Group of ESPGHAN

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Extraintestinal Manifestations are Associated with Disease Severity in Pediatric Onset Inflammatory Bowel Disease

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Preterm Birth Has Effects on Gut Colonization in Piglets Within the First 4 Weeks of Life

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Serum Calprotectin in Adolescents with Inflammatory Bowel Disease - A Pilot Investigation

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Outcomes Following Pouch Formation in Paediatric Ulcerative Colitis: A Study from the Porto Group of ESPGHAN

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Extraintestinal Manifestations are Associated with Disease Severity in Pediatric Onset Inflammatory Bowel Disease

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Letter: suicide risk among adult inflammatory bowel disease patients. Authors' reply

    Publikation: Bidrag til tidsskriftLetterForskningpeer review

  4. Telemedicin til monitorering af inflammatoriske tarmsygdomme og colon irritabile

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

OBJECTIVES: The aim of the study was to evaluate clinical response, use of colectomy, and adverse events related to infliximab (IFX) treatment in acute and chronic active ulcerative colitis (UC) in children.

METHODS: Children from 3 centers, who had received IFX for UC, were identified, and patient charts were reviewed retrospectively. Data concerning symptoms, biochemistry, concomitant medical treatment, colectomy, and adverse events were registered.

RESULTS: A total of 45 patients with UC (median age at diagnosis 12 years, interquartile range 10-14) were included, and studied for a median of 15 months (interquartile range 4.5-29) after first IFX infusion. The cumulative 1- and 2-year risks of colectomy were 21% and 26%, respectively. The cumulative 1- and 2-year risks of receiving a new course of systemic corticosteroids were 32% and 48%, respectively. Twenty-one patients (46%) experienced adverse events. Most common were mild infusion reactions, but 3 (7%) had serious adverse events.

CONCLUSIONS: IFX was efficient in preventing colectomy in children with UC. The risk of receiving systemic corticosteroids was lower than that reported in other studies. Most adverse events were mild to moderate and self-limiting.

OriginalsprogEngelsk
TidsskriftJournal of Pediatric Gastroenterology and Nutrition
Vol/bind58
Udgave nummer6
Sider (fra-til)768-72
Antal sider5
ISSN0277-2116
DOI
StatusUdgivet - jun. 2014

ID: 44833021